Research programme: Bispecific T cell engagers - Be Biopharma
Latest Information Update: 10 Nov 2023
At a glance
- Originator Be Biopharma
- Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma